ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "risk assessment"

  • Abstract Number: 889 • 2016 ACR/ARHP Annual Meeting

    The Utility of Patient-Reported Outcomes in Predicting Disease Activity in Patients with Takayasu’s Arteritis

    Antoine G. Sreih1, Tanaz A. Kermani2, Gunnar Tomasson3, Joshua F. Baker4, David Cuthbertson5, Renee Borchin6, Simon Carette7, Lindsy J. Forbess8, Gary S. Hoffman9, Nader A. Khalidi10, Curry L. Koening11, Carol A. McAlear12, Paul A. Monach13, Larry W. Moreland14, Christian Pagnoux15, Philip Seo16, Robert F. Spiera17, Kenneth J. Warrington18, Steven R. Ytterberg2, Carol A. Langford19 and Peter A. Merkel20, 1Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Rheumatology, Mayo Clinic, Rochester, MN, 3Dept of Public Health Sciences, University of Iceland, Reykjavik, IS, 4Rheumatology, University of Pennsylvania, Philadelphia, PA, 5Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, 6University of South Florida, Tampa, FL, 7Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 8Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 9Rheumatology, Cleveland Clinic, Cleveland, OH, 10Division of Rheumatology, McMaster University, Hamilton, ON, Canada, 11Rheumatology, University of Utah, Salt Lake City, UT, 12University of Pennsylvania, Philadelphia, PA, 13Rheumatology, Boston University School of Medicine, Boston, MA, 14Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 15Division of Rheumatology, Mount Sinai Hospital, University Health Network, University of Toronto, Toronto, Canada, Toronto, ON, Canada, 16Medicine, Johns Hopkins University, Baltimore, MD, 17Hospital for Special Surgery, Cornell, New York, NY, 18Rheumatology, University of California Los Angeles, CA, USA Mayo, Rochester, MN, 19Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 20Division of Rheumatology, Univ of Pennsylvania; Perelman School of Med, Philadelphia, PA

    Background/Purpose: Takayasu’s arteritis (TAK) is a relapsing large vessel vasculitis. There are currently no reliable predictors of disease relapse. This study explored whether changes in…
  • Abstract Number: 2018 • 2016 ACR/ARHP Annual Meeting

    A Clinical Risk Prediction Model for Skin Thickness Progression in Early Diffuse Scleroderma

    Robyn T. Domsic1, Mary Lucas2, Virginia D. Steen3 and Thomas A. Medsger Jr.4, 1Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 2Medicine, University of Pittsburgh Scleroderma Center, Pittsburgh, PA, 3Rheumatology, Georgetown University Medical Center, Washington, DC, 4Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose:   Systemic sclerosis (SSc) is a rapidly evolving field with multiple potential therapeutic agents under development and several active clinical trials focused on treating…
  • Abstract Number: 2430 • 2015 ACR/ARHP Annual Meeting

    Immunological Risk Factors after Rituximab Therapy in Patients with Pediatric Rheumatic Diseases – a Prospective Single-Center Study

    Fabian Speth1, Johannes Peter Haas1 and Claas Hinze2, 1German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, 2Department of Pediatric Rheumatology and Immunology, University Hospital Münster, Münster, Germany

    Background/Purpose: Rituximab (RTX) is used in refractory pediatric rheumatic diseases (PRD). Data regarding the effects of RTX on the immune system in children and safety…
  • Abstract Number: 2940 • 2015 ACR/ARHP Annual Meeting

    Risk Factors for Late-Onset Thrombosis in Systemic Lupus Erythematosus (SLE)

    Khawla Al-Ghanim1, Jiandong Su2, Stacey E. Morrison3, Samar Alharbi4, Mohammed Attar5, Dafna Gladman2, Murray Urowitz6,7 and Jorge Sánchez-Guerrero8, 1Rheumatology, TWH, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 3Div Rheumatology Rm MP-10-304, Toronto Western Hospital, Toronto, ON, Canada, 4Rheumatology, University Health Network, Toronto, ON, Canada, 5Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, 6University of Toronto, Toronto, ON, Canada, 7Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 8Rheumatology, Mount Sinai Hospital and University Health Network, Toronto Canada, Toronto, ON, Canada

    Background/Purpose: Thrombotic events (TE) cause great morbidity and mortality in SLE patients. Studies of TE in SLE focus on early-onset TE. While the incidence of…
  • Abstract Number: 166 • 2014 ACR/ARHP Annual Meeting

    Risk Factors for Gout Attack Recurrence during Urate-Lowering Allopurinol Treatment

    Myeong Jae Yoon1, Ji Ae Yang2, Sang Hyun Joo1, Sang Jin Lee1, Jin Young Moon1, Hyun Mi Kwon1, Dong Jin Ko1, Yeong Wook Song1 and Eun Bong Lee1, 1Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea

    Background/Purpose Gout is a recurrent inflammatory arthritis caused by crystal deposition of monosodium urate, which can be prevented urate-lowering agents such as allopurinol. However, gout…
  • Abstract Number: 7 • 2013 ACR/ARHP Annual Meeting

    Prospective Validation Of The Global Antiphospholipid Syndrome Score (GAPSS)

    Savino Sciascia1, Mª Jose Cuadrado2, Giovanni Sanna3, Veronica Murru4, Dario Roccatello1, Oier Ateka5, Munther A. Khamashta6 and Maria Laura Bertolaccini4, 1Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, 2Lupus Research Unit, The Rayne Institute, London, United Kingdom, 3Louise Coote Lupus Unit, St. Thomas' Hospital, London, United Kingdom, 4Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, 5Lupus Unit, London, United Kingdom, 6Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom

    Prospective Validation of the Global Antiphospholipid Syndrome Score (GAPSS) Background/Purpose: Backgrounds: This study was performed to prospectively and independently validate the GAPSS (1) (Global APS…
  • Abstract Number: 631 • 2012 ACR/ARHP Annual Meeting

    Peripheral Neuropathy Due to Systemic Lupus Erythematosus (SLE) Itself: Incidence, Disease Risk Factors and Outcome

    Simone Fargetti1, Samuel K. Shinjo2, Sandra G. Pasoto1, Ana L. Calich1, Eloisa Bonfa3 and Eduardo F. Borba1, 1Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, 2Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 3Rheumatology Division, University of São Paulo, Sao Paulo, Brazil

    Background/Purpose: Peripheral neuropathy (PN) solely attributable to SLE itself is difficult to define since most of these patients are exposed to several other conditions that…
  • Abstract Number: 605 • 2012 ACR/ARHP Annual Meeting

    Increased Incidence of Herpes Zoster Among Patients with Systemic Lupus Erythematosus

    Eliza F. Chakarvarty1, Kaleb Michaud2, Robert S. Katz3 and Frederick Wolfe4, 1Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, CA, 2Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE, 3Rush University Medical Center, Chicago, IL, 4National Data Bank for Rheumatic Diseases, Wichita, KS

     Background/Purpose:   Herpes zoster (HZ) is the painful reactivation of latent varicella zoster virus infection.  The incidence of HZ may be increased in some autoimmune…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology